Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
Summary Astellas came in with a mixed set of results, with growth across product segments balanced by challenges in U.S. sales. We are unsure about generic competitors posing a threat to XTANDI's market share. Profitability and economic profit continue to remain a standout, despite ...
The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2023 Q3 earnings call. For further details see: Astellas Pharma Inc. 2023 Q3 - Results - Earnings Call Presentation
Astellas Pharma ( OTCPK:ALPMF ): Q3 GAAP EPS of ¥103.61. Revenue of ¥1.17B. For further details see: Astellas Pharma GAAP EPS of ¥103.61, revenue of ¥1.17B
Summary Taysha has a good chance of scoring with the GAN indication. Astellas may license this program if that happens. However, the FDA's request for more patients is a critical problem. Since its IPO in September 2020, Taysha Gene Therapies ( TSHA ) stock price has b...
The US FDA has accepted supplemental Biologics License Applications from Merck ( NYSE: MRK ), Seagen ( NASDAQ: SGEN ), and Astellas ( OTCPK:ALPMF )( OTCPK:ALPMY ) for a combination of Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) for urotheli...
Astellas Pharma Inc. (ALPMF) Q3 2022 Earnings Conference Call October 31, 2022 04:00 a.m. ET Company Representatives Kenji Yasukawa - Chief Executive Officer Yoshitsugu Shitaka - CScO, Chief Scientific Officer Minoru Kikuoka - Chief Financial Officer Tadaaki ...
Astellas Pharma press release ( OTCPK:ALPMF ): 1H GAAP EPS of ¥65.78. Revenue of ¥762.18B (+17.0% Y/Y). For further details see: Astellas Pharma GAAP EPS of ¥65.78, revenue of ¥762.18B
Summary Twist Bioscience share price has fallen by 50% since the beginning of 2022. Management thinks DNA data storage could be $2 billion market for the company, aided by early mover advantage and investment in IP. Twist Bioscience recently raised full-year revenue guidance, ...
Summary Shares of early-stage prostate cancer concern ESSA Pharma Inc. are down 90% since May 2021 as trial data delays and vague messaging suggest that its therapy is running into issues about effectiveness and the market size for its therapy. It does not help that management has...
A jury has ordered Eli Lilly ( NYSE: LLY ) to pay $61M in a whistleblower case that accused the drugmaker of making false claims about pricing under Medicaid's drug pricing program, Bloomberg reported. The suit was filed in 2014 by whistleblower Ronald J. Streck wh...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...